Principal Investigator
Jaime Merchan
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20240570
Clinical Trial Summary
A FIRST-IN-HUMAN STUDY OF IK-595, AN ORAL DUAL
MEK/RAF INHIBITOR, IN PATIENTS WITH RAS- OR RAF-ALTERED
ADVANCED SOLID TUMORS
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
+1 (407) 7659589